Taxol extravasation: a case report.
Taxol is a relatively new antineoplastic agent whose classification as either vesicant, non-vesicant, or irritant remains under debate. This case study is presented to follow a large-volume Taxol extravasation. The article illustrates assessment, follow-up, intervention and outcome of this situation. This case suggests the drug is a vesicant with the potential to cause moderate soft tissue injury.
Bailey
W L
WL
Toronto Hospital, Ontario.
Crump
R M
RM
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D017326:Clinical Trials, Phase III as Topic; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000451:nursing*; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000009:adverse effects*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel